Slow N-acetylation as a possible contributor to bladder carcinogenesis

Area of Science:

• Urology
• Oncology
• Genetics

Background:

• Bladder cancer (BCa) is classified as noninvasive (NMIBC) or muscle-invasive (MIBC), with emerging molecular subtypes.
• Environmental and occupational arylamine exposure are significant BCa risk factors, metabolized by N-acetyltransferases (NAT1 and NAT2).
• Genetic polymorphisms in NAT1 and NAT2 influence arylamine metabolism and may impact BCa development and progression.

Purpose of the Study:

• To investigate the association between N-acetyltransferases (NAT1 and NAT2) genetic polymorphisms and key biomarkers/subtypes in bladder cancer (BCa).
• To explore the relationship between NAT1/NAT2 genotypes and tumor characteristics like muscle-invasiveness, grade, and specific gene mutations (TP53, RB1, FGFR3).

Main Methods:

• Genotyping of NAT1 and NAT2 was performed using real-time polymerase chain reaction (PCR) in a cohort of 250 male BCa patients.
• Tumor mutations in TP53, RB1, and FGFR3 were characterized via PCR-restriction fragment length polymorphism.
• Statistical analyses (Pearson χ2, Fisher exact tests) were used to assess associations between genetic polymorphisms and clinicopathological data.

Main Results:

• NAT1 G560A polymorphism showed significant associations with higher muscle-invasiveness (MIBC vs. NMIBC), increased tumor grade, and higher FGFR3 mutation frequency in MIBC.
• NAT2 G857A polymorphism was also significantly associated with higher muscle-invasiveness (MIBC vs. NMIBC).
• Patient smoking status was obtained from medical records.

Conclusions:

• Slow N-acetylation, influenced by NAT1 and NAT2 polymorphisms, appears to contribute to bladder carcinogenesis and the development of muscle-invasive bladder cancer.
• NAT1 is identified as a potential biomarker for BCa and a candidate for future drug development targeting bladder cancer progression.